Canaccord Genuity Maintains Hold Rating on Quipt Home Medical with $2.30 Price Target

Canaccord Genuity analyst Richard Close maintains a Hold rating on Quipt Home Medical with a price target of $2.30. The company's shares closed at C$3.65. Quipt Home Medical also received a Hold from TR | OpenAI – 4o's Lila Implantra on August 19, but Stifel Nicolaus maintained a Buy rating on August 12. QIPT market cap is C$158.1M with a P/E ratio of -10.92.

Quipt Home Medical (NASDAQ:QIPT) has seen a mix of analyst ratings and recent developments, with Canaccord Genuity analyst Richard Close maintaining a Hold rating with a price target of $2.30 [1]. The company's shares closed at C$3.65 on July 2, 2025, reflecting a slight increase from recent trading volumes. The market capitalization of Quipt Home Medical stands at C$158.1 million, with a P/E ratio of -10.92.

On August 19, TR | OpenAI – 4o's Lila Implantra also issued a Hold rating for Quipt Home Medical [1]. However, Stifel Nicolaus maintained a Buy rating on August 12, indicating a split in analyst opinions [1]. Despite the mixed ratings, institutional investors have shown interest in the company, with several major investors increasing their stakes in the fourth quarter of 2024 [1].

Quipt Home Medical has been the subject of a contested takeover bid by Forager Capital Management, which has faced scrutiny for its tactics and the valuation of its offer. The company's board has rejected the bid, arguing that it undervalues the company's strategic growth initiatives and recent financial resilience [2]. The board's focus on long-term value creation has drawn criticism for its opacity, but it has also garnered support from institutional investors, with 72.87% shareholder approval of the board at the March 2025 AGM [2].

The company's recent financial performance has shown resilience, with a 23.3% EBITDA margin despite a 6% year-over-year revenue decline in Q2 2025 [2]. Quipt Home Medical's strategic initiatives, such as expanding De Novo locations and pursuing healthcare system partnerships, position it to capitalize on the home healthcare market, which is valued at $150 billion [2].

In conclusion, Quipt Home Medical faces a mix of analyst ratings and a contested takeover bid, but its recent financial performance and strategic initiatives suggest potential for long-term growth. The company's market capitalization and P/E ratio indicate a relatively undervalued stock, presenting an opportunity for investors seeking long-term value.

References:
[1] https://www.marketbeat.com/instant-alerts/quipt-home-medical-nasdaqqipt-price-target-raised-to-230-at-canaccord-genuity-group-2025-08-19/
[2] https://www.ainvest.com/news/corporate-governance-shareholder-contested-takeovers-quipt-home-medical-case-study-2508/